What is GW Pharmaceuticals' stock price and ticker symbol?
What is GW Pharmaceuticals' stock symbol? GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH." What is GW Pharmaceuticals' stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
Should you hold GW Pharmaceuticals (gwph) stock?
The consensus among Wall Street research analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
How much does GW Pharmaceuticals make a year?
GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How many employees does GW Pharmaceuticals have? GW Pharmaceuticals employs 1,161 workers across the globe.
How do I get the latest gwph news and ratings?
Sign up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
See more
What happened to GWPH stock?
Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). GW shareholders gave the thumbs up to the deal last month. With the acquisition, Jazz gains access to GW's cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020.
Is GWPH a good stock to buy?
Based on analyst ratings, GW Pharma's 12-month average price target is $220.00. What is GWPH's upside potential, based on the analysts' average price target? GW Pharma has 0.47% upside potential, based on the analysts' average price target.
What is happening with GW Pharmaceuticals?
DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Who is buying GWPH?
On Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ 2.58%), both companies announced in a joint press release.
How much is GW Pharmaceuticals worth?
As of June 2022 GW Pharmaceuticals has a market cap of $6.81 Billion.
How much is a share of GW Pharmaceuticals?
What is GW Pharmaceuticals' stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
Does GW Pharmaceuticals still exist?
In May 2013, the company became dual-listed on the NASDAQ and AIM. In 2014, the company made a deal with New York to develop clinical trials using cannabidiol (CBD) to treat children who suffer from seizures and other medical complications. In May 2021, Jazz Pharmaceuticals acquired the company.
Is Jazz Pharmaceuticals an acquisition target?
Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. That is the British company that has the only FDA-approved CBD derived drug, Epidiolex. Jazz may be a new name for pot investors.
Who bought Greenwich Pharmaceuticals?
Jazzplc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash.
How much did Jazz Pharmaceuticals pay for GW Pharmaceuticals?
$7.2 billionJazz agreed to pony up $7.2 billion for cannabinoid hotshot GW Pharmaceuticals, whose epilepsy med Epidiolex could be on its way to blockbuster sales. The deal will move Jazz into the epilepsy market, expanding its current offerings beyond sleep disorders and cancer.
Who owns Jazz Pharmaceuticals?
Bruce C. CozaddJazz PharmaceuticalsTypePublic companyKey peopleBruce C. Cozadd (Chairman & CEO)ProductsPharmaceutical drugsBrandsXyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt VyxeosRevenueUS$1.618 billion (2017)13 more rows
Where is Jazz Pharmaceuticals headquarters?
IrelandJazz Pharmaceuticals / HeadquartersOur corporate headquarters are located in Dublin, Ireland. In the North America, we have offices in Palo Alto and Carlsbad, California; Philadelphia, Pennsylvania; Vancouver, British Columbia; and Mississauga, Ontario.
How were GW Pharmaceuticals' earnings last quarter?
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0....
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the following people: Mr. Justin D. Gover , CEO & Exec. Director (Age 50, Pay $1.19M) ( LinkedIn Pr...
What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com . Justin Gover has an approval rating of 80% among GW Pharmaceuticals...
Who are some of GW Pharmaceuticals' key competitors?
Some companies that are related to GW Pharmaceuticals include Royalty Pharma (RPRX) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Takeda Ph...
What other stocks do shareholders of GW Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC) , NVIDIA...
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."
What is GW Pharmaceuticals' stock price today?
One share of GWPH stock can currently be purchased for approximately $218.96.
How much money does GW Pharmaceuticals make?
GW Pharmaceuticals (NASDAQ:GWPH) has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceut...
How many employees does GW Pharmaceuticals have?
GW Pharmaceuticals employs 1,161 workers across the globe.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas.
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.27.
About GW Pharmaceuticals Plc
GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Stock Podcast
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
